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Scientific objective
Head and neck cancers (HNC) are among the most preva-
lent and deadly cancers. Despite advances in treatment
and improvement in patient’s quality of life, survival rates
have not improved in these patients. Increasing evidence
shows that the initiation, growth and metastasis of cancer
are directed by a small functional subpopulation of cancer
cells defined as cancer stem cells (CSCc). Multipotency
and differentiation into the tumor cells, plasticity and self-
renewal are among the most exclusive features of CSCs.
Programmed death 1 (PD-1) protein, is an inhibitory
T cell receptor which is able to muffle the immune
response of activated T cells, helping cancer cells to evade
the host defense system. Thus, we have examined the pre-
sence of CSCs in HNCs and if there is any correlation
between HNC development and PD-1 expression.
Technical approach/methods
Using tissue microarrays, we employed immunohisto-
chemistry and immunofluorescent protocols to explore
if CSCs marker, CD44, is expressed within the tumor
microenvironment. In addition, we investigated the pre-
sence of PD-1 expressing cells as inhibitors of antitumor
immunity.
Results/interpretation
We observed that a subpopulation of HNC expressed
CD44 which is suggestive of the presence of CSCs within
the tumor. Moreover, PD-1 was expressed within the
tumor microenvironment thereby indicating the pivotal
role of PD-1 in the suppression of the host immune sys-
tem and its significance for tumor survival and progression
of cancer. Collectively, the results not only re-emphasize
the role of CSCs in initiation and establishment of HNC,
but also suggest PD-1 as a novel therapeutic target in
anticancer frontier.
Outlook/expert recommendations
The present study suggests, for the first time, a relation
between cancer stem cells and programmed cell death 1
in head and neck cancer. Our findings indicate that the
presence of cancer stem cells in the head and neck tumor
and their association with the tumor structure may play a
crucial role not only in the establishment of the tumor,
but also, in the induction of immunosuppression status
of the immune system against head and neck tumors.
Therefore, subsequent studies should determine whether
any alteration in the presence and activity of cancer stem
cells within the tumor microenvironment can up-regulate
the immune responses against tumor growth and pro-
gression in the head and neck cancer. The primary thera-
peutic impact of such stimulation of immune system will
results in the focal disruptions of the tumor capsule,
which selectively favor tumor stem cells proliferation and
invasion.
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